(Q34569581)

English

Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

Reza Khosravan

1

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Brian A Grabowski

2

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Jing-Tao Wu

3

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Nancy Joseph-Ridge

4

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Laurent Vernillet

5

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

publication date

1 January 2006

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Clinical Pharmacokinetics

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

45

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

821-841

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

https://scigraph.springernature.com/pub.10.2165/00003088-200645080-00005

0 references

Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers.

1 reference

https://api.crossref.org/works/10.2165%2F00003088-200645080-00005

21 January 2018

The management of gout

1 reference

https://pubmed.ncbi.nlm.nih.gov/16884320

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency

1 reference

https://pubmed.ncbi.nlm.nih.gov/16884320

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment

1 reference

https://pubmed.ncbi.nlm.nih.gov/16884320

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Studies of uric acid pool size and turnover rate

1 reference

https://pubmed.ncbi.nlm.nih.gov/16884320

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/16884320

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incorporation of glycine nitrogen into uric acid in normal and gouty man

1 reference

https://pubmed.ncbi.nlm.nih.gov/16884320

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparative study on the hypouricemic activity and potency in renal xanthine calculus formation of two xanthine oxidase/xanthine dehydrogenase inhibitors: TEI-6720 and allopurinol in rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/16884320

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence and risk factors for gout in white men.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16884320

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Management of hyperuricemia with rasburicase review

1 reference

https://pubmed.ncbi.nlm.nih.gov/16884320

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Febuxostat compared with allopurinol in patients with hyperuricemia and gout

1 reference

https://pubmed.ncbi.nlm.nih.gov/16884320

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/16884320

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/16884320

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gout: the last 50 years.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16884320

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase

1 reference

https://pubmed.ncbi.nlm.nih.gov/16884320

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Xanthine stone formation

1 reference

https://pubmed.ncbi.nlm.nih.gov/16884320

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/16884320

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The metabolism of uric acid in the normal and gouty human studied with the aid of isotopic uric acid

1 reference

https://pubmed.ncbi.nlm.nih.gov/16884320

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents

1 reference

https://pubmed.ncbi.nlm.nih.gov/16884320

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase

1 reference

https://pubmed.ncbi.nlm.nih.gov/16884320

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16884320

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention and management of gout

1 reference

https://pubmed.ncbi.nlm.nih.gov/16884320

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout

1 reference

https://pubmed.ncbi.nlm.nih.gov/16884320

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00003088-200645080-00005

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34569581&oldid=2143927957"